Tesamorelin

Background

Tesamorelin is a synthetic growth hormone–releasing hormone (GHRH) analog developed to increase endogenous pulsatile growth hormone secretion and downstream insulin-like growth factor-1 (IGF-1) signaling. It was first studied as TH9507 in clinical development and later marketed as Egrifta and, in the reformulated product, Egrifta SV for HIV-associated lipodystrophy with excess visceral adipose tissue (VAT) [12]. The molecule was designed to improve the stability and bioactivity of native GHRH while retaining receptor agonism [10][12]. In mechanistic human studies, tesamorelin has been shown to augment physiologic GH pulsatility rather than replacing GH directly [11].

The main clinical origin of tesamorelin is metabolic complications in people living with HIV, particularly central adiposity and elevated VAT that persisted despite antiretroviral therapy [12]. In broader peptide-therapeutics research, tesamorelin is also cited as a prototypic long-acting GHRH agonist used to explore GH-axis modulation in cardiometabolic and regenerative settings, although these uses remain investigational [3][4].

Mechanism of action

Tesamorelin acts as an agonist at the GHRH receptor on pituitary somatotrophs, stimulating physiologic GH release and increasing circulating IGF-1 [11][12]. In healthy men, a 2 mg daily subcutaneous dose increased endogenous GH pulsatility over 2 weeks, supporting receptor-mediated activation of the GH axis rather than a continuous GH replacement effect [11].

Its clinical effect on VAT is thought to be mediated primarily through GH-driven shifts in lipid mobilization and regional fat partitioning, with less effect on subcutaneous adipose tissue than on visceral stores [12]. The exact downstream pathways responsible for VAT reduction remain incompletely defined, but the established pharmacodynamic marker is a rise in IGF-1 and GH output after treatment [11][12].

Evidence summary

The most cited human evidence comes from multicenter placebo-controlled studies in HIV-associated abdominal fat accumulation. In the pooled analysis of two phase 3 trials, 404 participants received tesamorelin 2 mg daily subcutaneously or placebo, with a subset entering a 52-week extension; tesamorelin significantly reduced VAT by computed tomography and improved waist circumference and fasting triglycerides, with maintenance of VAT reduction in those continuing treatment [12]. The pooled report also found no clinically meaningful differences in glucose parameters at 26 or 52 weeks in the study population overall [12].

A smaller mechanistic study in 13 healthy men evaluated 2 weeks of tesamorelin 2 mg daily and showed increased endogenous GH pulsatility and assessed insulin sensitivity as a secondary endocrine outcome [11]. This study is important because it supports the physiologic basis of tesamorelin’s action, but it was short, small, and not a disease-outcomes trial [11].

Preclinical literature is broader but less directly relevant to approved use. A 2024 review of GHRH signaling summarized animal data suggesting cardioprotective effects of GHRH analogs, including improved myocardial function, reduced oxidative stress, and less remodeling, but it also emphasized that clinical translation remains limited by route-of-administration issues and potential GH/IGF-1–related adverse effects [3]. Experimental optimization work has produced longer-acting GHRH agonists that improve tissue perfusion in hindlimb ischemia models, underscoring the biologic plausibility of the class but not establishing tesamorelin itself for vascular indications [4].

Clinical and research uses

Tesamorelin is approved in the United States for reduction of excess abdominal fat in adults with HIV-associated lipodystrophy [12]. In published trials, its effect is specifically on visceral abdominal fat rather than generalized weight loss [12]. Case-based literature continues to discuss its use in people living with HIV who have prominent visceral adiposity, often in the context of cardiometabolic risk reduction [1].

Investigational and off-label research uses have included endocrine physiology, cardiometabolic disease, and regenerative biology. Reviews of the GHRH field describe tesamorelin and related analogs as candidates for cardiac repair and vascular remodeling, but these remain preclinical or early translational concepts rather than established indications [3][4].

Dosing context

The commonly reported clinical regimen is 2 mg subcutaneously once daily, which was used in the phase 3 HIV lipodystrophy program and in mechanistic endocrine studies [11][12]. The pooled phase 3 analysis included 26-week treatment periods and a 26-week extension in which some participants continued tesamorelin while others switched from placebo [12]. Literature reports should be interpreted as study dosing context rather than a recommendation for individual prescribing.

Safety profile

Tesamorelin was generally well tolerated in the major HIV trials, but adverse effects were consistent with activation of the GH/IGF-1 axis and with injection-based peptide therapy [12]. Across clinical studies and regulatory documents, the main safety concerns include increased IGF-1, glucose intolerance or hyperglycemia, arthralgia, edema, and injection-site reactions [12]. The healthy-men mechanistic study was small and short, so it does not define long-term safety [11].

Clinically relevant contraindications and warnings have centered on active malignancy and conditions in which increased endogenous GH/IGF-1 may be undesirable, along with hypersensitivity to product components; labeling also advises caution in patients with impaired glucose tolerance or diabetes because of potential glycemic worsening [12]. Because tesamorelin promotes the GH axis, it is also considered inappropriate in patients with acute critical illness or other settings where GH-axis stimulation is unsafe or not studied, although such exclusions are often handled through trial eligibility and labeling rather than a class-wide prohibition [12].

Regulatory status

In the United States, tesamorelin is an FDA-approved prescription drug for reduction of excess abdominal fat in adults with HIV-associated lipodystrophy, marketed as Egrifta SV; older Egrifta presentations were also approved for this indication [12]. In the European Union, tesamorelin does not have an established centralized EMA marketing authorization for this indication, so it is generally regarded as not EU-approved for routine use. The evidence base for non-HIV indications remains investigational, with preclinical and early translational interest but no broad regulatory approval [3][4].